EndoChoice Announces Pricing of Its Initial Public Offering

Atlanta, GA (ots) - June 4, 2015 - EndoChoice today announced the
pricing of its initial public offering of 6,350,000 shares of its
common stock at a price to the public of $15.00 per share. The
offering is scheduled to close on June 10, 2015, subject to customary
closing conditions. The underwriters for the offering will also have
a 30-day option to purchase up to an additional 952,500 shares of
EndoChoice common stock at the price to the public, less the
underwriting discounts and commissions.

EndoChoice common stock is expected to begin trading on the New
York Stock Exchange on June 5, 2015 under the symbol "GI". J.P.
Morgan and BofA Merrill Lynch are acting as joint book-running
managers for the offering. William Blair and Stifel are acting as
co-managers for the offering.

A registration statement relating to these securities has been
filed with the Securities and Exchange Commission and was declared
effective on June 4, 2015. The offering is being made only by means
of a prospectus, copies of which may be obtained from J.P. Morgan
Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island
Avenue, Edgewood, NY 11717 or by telephone: +1 (866) 803-9204); or
BofA Merrill Lynch, Attention: Prospectus Dept., 222 Broadway, New
York, NY 10038, or: dg.prospectus_requests@baml.com. This press
release shall not constitute an offer to sell or the solicitation of
an offer to buy, nor shall there be any sale of these securities in
any state or jurisdiction in which such offer, solicitation or sale
would be unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.

About EndoChoice

Based in the Atlanta, Georgia area, EndoChoice is a medtech
company focused on the manufacturing and commercialization of
platform technologies including endoscopic imaging systems, devices
and infection control products and pathology services for specialists
screening, diagnosing and treating a wide range of gastrointestinal
conditions, including colon cancer. EndoChoice leverages its direct
sales organization to serve more than 2,500 customers in the United
States and works with distribution partners in 25 countries. The
Company was founded in 2008 and has developed a broad and innovative
product portfolio, which includes the Full Spectrum Endoscopy® System
(Fuse®).

Source: EndoChoice, Inc.

###

EndoChoice, Fuse, and Full Spectrum Endoscopy are registered
trademarks of EndoChoice, Inc.

For more information:

Company Contact
David Gill, Chief Financial Officer
david.gill@endochoice.com
678-585-1040